


ESTRO & EORTC Registry trial: OligoCare

Matthias Guckenberger, Piet Ost
on behalf of the OligoCare project




OLIGOMETASTASES

Localized




Cure with local treatment

Oligometastatic



Cure with local treatment possible

Systemic



Local Tx for symptom control

Hellman & Weichselbaum JCO 1995

➤ The beauty: a simple concept

Future evidence generation

1	Recruiting	Radiotherapy for Oligometastatic Prostate Cancer Condition: Oligometastatic Prostate Cancer Intervention: Radiation; Stereotactic radiation
2	Recruiting	The Value of Radiotherapy in Oligometastatic Non-small Cell Lung Cancer With Clinical Benefit From First-Line Systemic Therapy Condition: Oligometastatic Non-small Cell Lung Cancer Intervention: Radiation; Radiotherapy
3	Completed	Phase II Trial of Stereotactic Radiotherapy for Oligometastatic Non-small Cell Lung Cancer Condition: NSCLC Intervention: Radiation; Radiotherapy
4	Recruiting	Phase III Trial of Stereotactic Radiotherapy for Oligometastatic Non-small Cell Lung Cancer Condition: Non-small Cell Lung Cancer Intervention: Radiation; Radical Radiotherapy (Conventional); Stereotactic Radiotherapy; Non-investigational platinum-based chemotherapy
5	Not yet recruiting	Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer Condition: NSCLC Intervention: Radiation; Conventional Radiotherapy; Radiation; Stereotactic Radiotherapy
6	Recruiting	Stereotactic Radiotherapy for Oligometastatic Prostate Cancer Condition: Prostate Cancer Intervention: Radiation
7	Recruiting	Carbon Ion Radiotherapy in Combination With Systemic Therapy for Oligometastatic Prostate Cancer Condition: Prostate Cancer Intervention: Radiation; Carbon Ion Radiotherapy; Systemic Therapy; Anti-androgen Therapy; Anti-androgen Therapy arm
8	Recruiting	The Optimal Intervention for Oligometastatic Stage IV Non-small Cell Lung Cancer Condition: Oligometastatic Stage IV Non-small Cell Lung Cancer Intervention: Radiation; concurrent chemotherapy; Drug; Docetaxel; Drug; gemtuzumab; Drug; paclitaxel
9	Active, not recruiting	Salvage Radiotherapy Compared With Systemic Therapy in Oligometastatic Prostate Node Relapses of Prostate Cancer Condition: Prostate Cancer Intervention: Radiation; Systemic Therapy
10	Recruiting	Non-investigational Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer Condition: Various Cancers Intervention: Radiation; Stereotactic Body Radiation Therapy

primary tumour

type & stage
treatment & response

oligometastases

definition & diagnosis
timing
numbers & size
nodal vs. distant
organs & location

treatment


dose & fractionation
technique & technology
other treatment modalities

trial & endpoints

survival vs. intermediary endpoints
QOL & PROMs
cost data

OligoCare

A Pragmatic Observational Basket Study
to Evaluate Radical Radiotherapy for
Oligo-Metastatic Cancer Patients



Study Objectives

- To assess patterns-of-care and patterns-of-outcome of stereotactic radiotherapy for oligometastatic disease
- To identify patient, tumor and treatment characteristics influencing safety and efficacy


Benefits from participation

- Participation open to ALL radiotherapy centres, not "ONLY" EORTC members of academic institutions (participating countries tbd based on feasibility survey)
- Open and transparent data sharing policy
 - All participating centres can apply for data access and research projects
- Possibility of regular benchmarking of your institution
 - optional AND anonymous
- Consideration in all publications, considering active participation
- Certification as participating institution
- Increase in study activity and increase in proportion of patients in clinical trials
-


OligoCare: inclusion criteria

- Patients are eligible irrespective whether oligometastatic disease is diagnosed synchronously or metachronously.
- There are no restrictions with respect to prior surgical, locally ablative, radiotherapy and systemic treatments performed
- ALL visible cancer lesions (loco-regional primary and all oligometastases) are treated with radical intent. There is no upper limit of metastases treated radically
- Radical radiotherapy must be a component of treatment of oligometastases.
- Primary disease types: non small cell lung cancer, breast cancer, prostate cancer, colorectal cancer.

OligoCare: Study Design



OligoCare: data collection & storage



Current status

- Protocol finished
- e-CRF in development
- Feasibility survey distributed during / after this ESTRO meeting

Interested ? – please register !

OligoCare - Pragmatic Observational Basket Study
to Evaluate Radical Radiotherapy for
Oligo-Metastatic Cancer Patients

Interested to participate? Register at:

<https://eortc.wufoo.eu/forms/samy6re10j7jz0/>

CONCLUSIONS

- SBRT for oligo-metastases has arrived as a standard of care,
 - despite lack of hard evidence
 - despite huge uncertainties & variability in practice
- Traditional clinical trials will not answer all answers
- **OligoCare:**
 - Joint initiative between ESTRO & EORTC
 - Collaborative, Global, Pragmatic, Adaptive

Matthias Guckenberger
Yolande Lievens
Umberto Riccardi
Dirk Verellen
Alejandra Mendez Romero
Martra Scorsetti
Christine Verfaillie

Piet Ost
Laurence Collette
Sandra Collette
Beatrice Fournier
Coen Hurkmans
Yan Liu
Bertrand Tombal

ESTRO 

 **EORTC**
The future of cancer therapy

*Thank you for your attention,
and looking forward to our collaboration!*